[Modern treatment of autosomal dominant polycystic kidney disease].
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common causes of end stage renal failure (ESRF). Nevertheless, until now the standard therapy of ADPKD consists merely of nephroprotection and treatment of complications. In the sixth decade of life in about 50% of patients renal replacement therapy is initiated. Surgery procedures such as nephrectomy and renal contraction therapy are performed in some patients. In 21st century numerous studies concerning patophysiology of the disease (role of polycystins, intracellular calcium, cAMP) were published and gave an impulse for searching new drugs that could slower progression of ADPKD. Somatostatin receptor agonists, vasopressin V2 receptor antagonists, rapamycin, and tyrosine kinase inhibitors are among medications that are thought to be effective. Although it is unclear if any of these drugs will be really effective there are strong theoretical backgrounds and promising results of experimental studies on animals. Nephrologists and their patients are waiting for the results of clinical trials that are performed now.
Wołyniec
Wojciech
W
Akademia Medyczna w Gdańsku, Klinika i Katedra Nefrologii, Transplantologii i Chorób Wewnetrznych. wwolyniec@wp.pl
Jankowska
Magdalena Maria
MM
Rutkowski
Bolesław
B
D006801:Humans; D008875:Middle Aged; D009392:Nephrectomy; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome